Molecular Partners AG
molecularpartners.comWhat Do They Do?
Develops protein-based drug candidates for cancer treatment, including targeted radioactive therapies and medicines designed to direct immune cells against tumors.
20-F for FY2025, filed Mar 12, 2026
Who Are Their Customers?
Biopharmaceutical companies and other collaborators work with Molecular Partners through drug-development and research collaborations.
20-F for FY2025, filed Mar 12, 2026We have strategic collaboration agreements with Orano Med, and other third party collaborators.View ↗
h.Continue a strategic approach to in-house versus partnered development. To unlock and expand the full potential of our DARPin platforms…View ↗
i.This strategy has allowed us to pursue major therapeutic innovations for the DARPin platform, often in parallel, across our oncology…View ↗
How Are They Changing?
Oncology emphasis
The older report described oncology and virology as focus areas; the latest describes its pipeline as having a main focus on oncology, particularly cancer therapies.
20-F for FY2022, filed Mar 9, 2023 20-F for FY2025, filed Mar 12, 2026
Loading...
